{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:36:33Z","timestamp":1794670593805,"version":"4.9.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["75N95019C00054"],"award-info":[{"award-number":["75N95019C00054"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","annemergmed.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.annemergmed.2024.01.041","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T09:00:35Z","timestamp":1710579635000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7073-9060","authenticated-orcid":false,"given":"Jeanmarie","family":"Perrone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Haroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"D\u2019Orazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Gianotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Love","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Salzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Lowenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Thakrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Klipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Rae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan K.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Sisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Wightman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis S.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2024.01.041_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl\u2013involved overdose deaths with detected xylazine \u2014 United States, January 2019\u2013June 2022","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib5","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1080\/15563650.2022.2063135","article-title":"Xylazine poisoning: a systematic review","volume":"60","author":"Ball","year":"2022","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/15563650.2022.2159427","article-title":"Opioid overdoses involving xylazine in emergency department patients: a multicenter study","volume":"61","author":"Love","year":"2023","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib7","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-2999(73)90102-7","article-title":"Evidence for increased vagal\u00a0tone and enhancement of baroreceptor reflex activity after\u00a0xylazine (2-(2,6-dimethylphenylamino)-4-H-5,6-dihydro-1,3-thiazine) in anesthestized dogs","volume":"23","author":"Antonaccio","year":"1973","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib8","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2460\/ajvr.81.2.159","article-title":"Effects of imidazoline and nonimidazoline \u03b1-adrenoceptor agonists and antagonists, including xylazine, medetomidine, dexmedetomidine, yohimbine, and atipamezole, on aggregation of feline platelets","volume":"81","author":"Matsukawa","year":"2020","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: A comprehensive review of the literature","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib11","unstructured":"Thakrar AP, Zweibel S, Davis MH, et\u00a0al. Manifestations of xylazine exposure among hospitalized patients in Philadelphia: a retrospective cohort study. Oral presentation at the Society of General Internal Medicine (SGIM) National Conference. Aurora, CO. May 12, 2023."},{"key":"10.1016\/j.annemergmed.2024.01.041_bib13","author":"Green"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1467-2987.2004.00144.x","article-title":"A\u00a0comparison of two intramuscular doses of xylazine-ketamine combination and tolazoline reversal in llamas","volume":"31","author":"DuBois","year":"2004","journal-title":"Vet Anaesth Analg"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199087","article-title":"Faster emergence behavior from ketamine\/xylazine anesthesia with atipamezole versus yohimbine","volume":"13","author":"Mees","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108147","article-title":"Protracted renal clearance of fentanyl in persons with opioid use disorder","volume":"214","author":"Huhn","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib17","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.annemergmed.2022.05.032","article-title":"A\u00a0Neuropharmacological model to explain buprenorphine induction challenges","volume":"80","author":"Greenwald","year":"2022","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib18","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1001\/jama.1979.03300190044026","article-title":"Abrupt discontinuation of clonidine therapy","volume":"242","author":"Ram","year":"1979","journal-title":"JAMA"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.psym.2016.05.001","article-title":"Xylazine dependence and detoxification: a case report","volume":"57","author":"Mulders","year":"2016","journal-title":"Psychosomatics"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jcrc.2020.10.024","article-title":"Evaluation of dexmedetomidine withdrawal in critically ill adults","volume":"62","author":"Pathan","year":"2021","journal-title":"J\u00a0Crit Care"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib21","first-page":"595","article-title":"Management of xylazine withdrawal in a hospitalized patient: a case report","volume":"16","author":"Ehrman-Dupre","year":"2022","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib22","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.7326\/M23-2001","article-title":"Xylazine adulteration of the heroin-fentanyl drug supply: a narrative review","volume":"176","author":"D\u2019Orazio","year":"2023","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib24","first-page":"9","article-title":"Xylazine-associated wounds: clinical experience from a low-barrier wound care clinic in Philadelphia","volume":"18","author":"McFadden","year":"2024","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib25","first-page":"80","article-title":"Muscle necrosis in Syrian hamsters resulting from intramuscular injections of ketamine and xylazine","volume":"37","author":"Gaertner","year":"1987","journal-title":"Lab Anim Sci"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000097654","article-title":"Influence of different anesthetics on skin oxygenation studied by electron paramagnetic resonance in\u00a0vivo","volume":"20","author":"Abramovic","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib27","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cca.2021.07.010","article-title":"High prevalence of xylazine among fentanyl screen-positive urines from hospitalized patients, Philadelphia, 2021","volume":"521","author":"Korn","year":"2021","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib28","first-page":"121","article-title":"Implementation of urine xylazine\u00a0testing by GC-MS in patients with substance use: experience\u00a0from a multicenter hospital system","volume":"19","author":"Black","year":"2023","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib29","first-page":"691","article-title":"Self-reported xylazine experiences: a mixed-methods study of Reddit subscribers","volume":"17","author":"Spadaro","year":"2023","journal-title":"J\u00a0Addict Med"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib30","first-page":"131","article-title":"Drug overdose testing (DOT) preliminary service data acceptability and feasibility","volume":"19","author":"Wightman","year":"2023","journal-title":"J\u00a0Med Toxicol"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.forc.2023.100489","article-title":"An analytical platform for near real-time drug landscape monitoring using paraphernalia residues","volume":"34","author":"Appley","year":"2023","journal-title":"Forensic Chem"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.15585\/mmwr.mm7217a2","article-title":"Rapid analysis of drugs: a pilot surveillance system to detect changes in the illicit drug supply to guide timely harm reduction responses \u2014 eight syringe services programs, Maryland, November 2021\u2013August 2022","volume":"72","author":"Russell","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2023.104118","article-title":"Comprehensive testing and rapid dissemination of local drug supply surveillance data in Rhode Island","volume":"118","author":"Collins","year":"2023","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib35","author":"Krotulski"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/dta.3612","article-title":"Understanding sensitivity and cross-reactivity of xylazine lateral flow immunoassay test strips for drug checking applications","author":"Sisco","year":"2023","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.annemergmed.2024.01.041_bib37","article-title":"Perspectives of people in Philadelphia who use fentanyl\/heroin adulterated with the animal tranquilizer xylazine; making a case for xylazine test strips","volume":"4","author":"Reed","year":"2022","journal-title":"Drug Alcohol Depend Rep"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064424000805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064424000805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T18:25:51Z","timestamp":1718821551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064424000805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0196064424000805"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2024.01.041","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2024.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}